2019-nCoV (SARS-CoV-2) vaccine

Optimized polynucleotides encoding the 2019-nCoV spike protein address the lack of effective vaccines by enhancing expression and inducing neutralizing antibodies, enabling large-scale production and effective prevention/treatment of 2019-nCoV infections.

JP2026086596APending Publication Date: 2026-05-26VAXBIO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
VAXBIO LTD
Filing Date
2026-02-06
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

There is a need for the development of antigens that can be used in vaccines to prevent and treat 2019-nCoV infection, particularly those that can be produced inexpensively and on a large scale, as no effective vaccine exists for the virus, and information on its epidemiological and clinical characteristics is lacking.

Method used

Development of polynucleotides encoding the 2019-nCoV spike protein optimized for expression in various host cells, along with vectors and conjugation compounds like antibodies and antibody-like molecules, to induce an immunoprotective response through the production of neutralizing antibodies.

Benefits of technology

The optimized polynucleotides enhance the expression and duration of the 2019-nCoV spike protein, facilitating large-scale production and inducing a potent antibody response, thereby providing effective prevention and treatment options for 2019-nCoV infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026086596000051
    Figure 2026086596000051
  • Figure 2026086596000052
    Figure 2026086596000052
  • Figure 2026086596000053
    Figure 2026086596000053
Patent Text Reader

Abstract

We provide a vaccine against 2019-nCoV infection. [Solution] A fusion protein is provided comprising a spike protein derived from 2019-nCoV having at least 90% identity with a specific sequence; or a fragment thereof having common antigen cross-reactivity with the spike protein, wherein the fragment may preferably include, or consist of, a receptor-binding domain (RBD) of the 2019-nCoV spike protein having at least 90% identity with a specific sequence.
Need to check novelty before this filing date? Find Prior Art